Frequently asked

A 2,123 bp chimeric receptor-effector gene therapy construct fusing the human NKG2D ectodomain to the elephant LIF6 mitochondrial apoptosis effector. Single AAV9 payload, no autologous cell processing.

LIF6 is the re-functionalized pseudogene that drives the elephant cancer-resistance phenotype behind Peto's Paradox (Vazquez et al. 2018, Cell Reports). It is a single-purpose mitochondrial puncher with cleaner pharmacology than upstream sensors like TP53, which is pleiotropic.

No. CAR-T requires extracting and engineering a patient's own T cells then reinfusing — significant manufacturing complexity. NKG2D-LIF6 is a single-construct gene therapy delivered as one AAV9 payload, no autologous cell processing required.

Clean IP whitespace on the specific NKG2D-LIF6 chimera. Provisional patent in progress. Comprehensive freedom-to-operate analysis complete; no prior art identified on the combination.

Pre-seed. In silico validation complete (~99% TGI ceiling on CRC syngeneic models). In vivo validation in three syngeneic murine tumor models planned for Q2 2026. Pre-IND meeting target H2 2026. First-in-human Phase 1 target 2027.

Wyoming LLC, EIN 39-4373044. Solo founder + production AI agent stack. Will convert to Delaware C-corp at Series A or earlier as required by lead investor.

Send a brief note to investors@nightboxllc.com (firm, focus areas, ticket size, lead-vs-follow). We share data-room access within 24 hours and schedule a working call. Round and use-of-proceeds detail at /investors.

Yes. Real Claude through Vercel AI Gateway with full Nightbox context. It can answer technical questions about NKG2D-LIF6 directly. Site infrastructure: Vercel Edge runtime, streaming SSE, prompt-injection defense, output sanitization.

Email partnerships@nightboxllc.com with a one-paragraph fit hypothesis. We respond to every well-targeted note.

press@nightboxllc.com · factsheet at /press